产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0371-1.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0371-2.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0371-3.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0371-4.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0371-5.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨细胞) (STR鉴定正确)](/Public/upfile/pic/xbx/CL-0371-6.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨细胞) (STR鉴定正确)](/Public/upfile/pic/product/cell-line-new.jpg)
产品概述
| 名称 | K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨细胞) (STR鉴定正确) |
| 别称 | K7M2 wt; K7M2 |
| 种属 | 小鼠 |
| 生长特性 | 贴壁细胞 |
| 细胞形态 | 成骨细胞样 |
| 冻存条件 | 冻存液：55% 基础培养基+40%FBS+5%DMSO 温度：液氮 |
| 培养方案A（默认） |
培养条件:
气相：空气，95%；CO2，5%, 温度：37℃
|
| 推荐传代比例 | 1:3-1:4 |
| 推荐换液频率 | 2-3次/周 |
| 背景描述 | K7M2 wt [K7M2-WT]细胞抗原表达：Ⅷ因子、整合唾液酸蛋白(BSP)、二聚糖、饰胶蛋白聚糖、绒毛蛋白。此外，骨唾液酸蛋白、二聚糖、饰胶蛋白聚糖和骨调素的表达显示K7M2 wt [K7M2-WT]细胞骨家族细胞特性。 |
| 年龄（性别） | 雌性；成年 |
| 组织来源 | 品系：BALB/c；器官：骨；疾病：骨肉瘤；来源转移灶：肺；细胞类型：成骨细胞 |
| 细胞类型 | 肿瘤细胞 |
| 肿瘤类型 | 肉瘤细胞 |
| 生物安全等级 | BSL-1 |
| 倍增时间 | ~31 hours |
| 致瘤性 | Yes, forms tumors in BALB/c mice with spontaneous metastasis to the lungs in over 90% of mice inoculated. |
| 抗原表达情况 | CD31+ |
| 基因表达情况 | secreted phosphoprotein 1 (osteopontin); factor VIII |
| 保藏机构 | ATCC; CRL-2836 |
STR鉴定
-
STR位点信息
18-3 18 6-7 12 5-5 14 X-1 25 1-2 17 7-1 29 8-1 13,14 1-1 16 19-2 13 15-3 22.3 12-1 17 6-4 18 4-2 21.3 3-2 12,13 2-1 16 13-1 16.2
11-2 18 17-2 16,17 -
STR鉴定图
-
参考文献
-
Nanoengineering a metal–organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells(2022/05/03)
作者：Qingxin Fan, Jing Zuo, Hailong Tian
期刊：JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
DOI：10.1186/s13046-022-02372-8
影响因子 ：11.300
引用产品：CL-0371
-
Injectable thermosensitive black phosphorus nanosheet- and doxorubicin-loaded hydrogel for synergistic bone tumor photothermal-chemotherapy and osteogenesis enhancement(2023/03/25)
作者：Shihuai Li, Yunan Qing, Yan Lou
期刊：INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
DOI：10.1016/j.ijbiomac.2023.124209
影响因子 ：8.200
-
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression(2022/01/12)
作者：Jinti Lin, Ankai Xu, Jiakang Jin
期刊：OncoImmunology
DOI：10.1080/2162402X.2021.2024941
影响因子 ：7.200
-
Pharmacodynamics and pharmacokinetics of PLGA-based doxorubicin-loaded implants for tumor therapy(2022/02/29)
作者：Peng He, Shenglin Xu, Zehao Guo
期刊：Drug Delivery
DOI：10.1080/10717544.2022.2032878
影响因子 ：6.000
引用产品：CL-0371
-
Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment(2023/06/08)
作者：Song Liao, Jianxiong Li, Song Gao
期刊：Frontiers in Oncology
影响因子 ：4.700
-
LPS combined with CD47mAb enhances the anti‑osteosarcoma ability of macrophages(2023/03/28)
作者：Peng Yuan, Yukang Que, Yulei Liu
期刊：Oncology Letters
影响因子 ：2.900
